Safety Study of JTT-302 in Subjects With Low HDL-C Levels
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of JTT-302 when administered for eight or
12 weeks in subjects with low HDL-C levels and to determine the effect of JTT-302 on lipid
parameters and CETP activity and mass.